New drug for post-herpetic neuralgia shows promise despite missing primary efficacy endpoint

New drug for post-herpetic neuralgia shows promise despite missing primary efficacy endpoint

An investigational drug called LX9211 could be the first-in-class treatment for post-herpetic neuralgia (PHN), a type of neuropathic pain that can occur after shingles. According to researcher Anand Patel, MD, of Conquest Research in Florida, the drug inhibits adapter protein 2-associated kinase-1 (AAK1), which is known to cause neuropathic pain. The drug performed well in a phase II study with 79 patients, showing a 2.42-point decrease in average daily pain scores after 6 weeks. However, the primary efficacy endpoint was missed due to a high rate of adverse events leading to early dropouts. A new study is being developed to optimize the dosing of LX9211.

AAK1 has emerged as a promising target for neuropathic pain therapy, and LX9211 has shown significant reductions in pain scores for diabetic neuropathy in a previous study. In the new trial, called RELIEF-PHN1, patients were randomized to LX9211 or placebo, with the drug showing a clear advantage in a secondary outcome. However, adverse events were more common with the active agent, with dizziness reported by 29% of patients on LX9211 compared to 5% of the placebo group. Patel believes that this may have been due to a large loading dose, and a new trial is being developed to test other dosing regimens.

Despite missing the primary efficacy endpoint, LX9211 still shows promise for the treatment of PHN, and the development of a non-opioid drug for neuropathic pain would be a significant breakthrough for patients.


Articles You May Like

FDA Approves Paxlovid for Treating COVID-19 in High-risk Outpatients
Tentative Deal Reached on US Debt Ceiling
Paloma Faith Criticizes The Little Mermaid Storyline
California Film Incentives Program Sees Half of Projects Seek “Force Majeure” Extension Due to Writers Guild Strike

Leave a Reply

Your email address will not be published. Required fields are marked *